The present disclosure relates to genetically engineered host cells and methods of producing a lipid-derived compound by employing such host cells. In particular embodiments, the host cell includes a first mutant gene encoding a cytoplasmic tRNA thiolation protein. Optionally, the host cell can include other mutant genes for decreasing fatty alcohol catabolism, decreasing re-importation of secreted fatty alcohol, or displaying other useful characteristics, as described herein.

A system and method for production of fatty acid ethanolamides (FAEs) are provided. The system and method for production of fatty acid ethanolamides includes microbes engineered to express the necessary enzymes to complete a FAE biosynthetic pathway, resulting in the conversion of glucose to one or more desired FAEs. The microbes may be engineered to express at least two of thioesterase, fatty acyl CoA synthase, NAPE-synthase, and NAPE phospholipase-D. The FAE-producing microbes can be administered to a subject in need thereof as part of a probiotic regimen.

The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.

The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.

Recombinant microbial cells are disclosed herein that produce an oil comprising at least 28 percent eicosapentaenoic acid (EPA) measured as a weight percent of dry cell weight. These cells may comprise a polynucleotide sequence encoding an active acyl-CoA:lysophosphatidylcholine acyltransferase (LPCAT) comprising at least one amino acid mutation in a membrane-bound O-acyltransferase motif. In addition, the cells may comprise a down-regulation of an endogenous polynucleotide sequence encoding Sou2 sorbitol utilization protein, and/or one or more polynucleotides encoding phospholipid:diacylglycerol acyltransferase (PDAT), delta-12 desaturase, a dihomo-gamma-linolenic acid (DGLA) synthase multizyme, delta-8 desaturase, malonyl-CoA synthetase (MCS), or acyl-CoA:lysophosphatidic acid acyltransferase (LPAAT). Also disclosed are methods of using the recombinant microbial cells to produce oil containing omega-3 polyunsaturated fatty acids such as EPA.

The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.

Fusion proteins comprising a tafazzin peptide and a cellular permeability peptide are disclosed. The tafazzin peptide may be coupled to the permeability peptide through a polypeptide linker. Methods of making and using the fusion proteins are also disclosed. For example, the disclosed fusion proteins may be used to treat a patient having a disorder associated with a tafazzin deficiency or a remodeled cardiolipin deficiency (e.g., Barth syndrome). Additionally, the disclosed fusion proteins may be used in prophylaxis against developing a disorder associated with a tafazzin deficiency or a remodeled cardiolipin deficiency in a patient at risk of developing such a disorder.

Provided are systems and methods for converting C1 substrates to products contain more than one carbon, without producing central metabolic building blocks as intermediate products. In an embodiment, system/method can include a biochemical pathway enabling an orthogonal platform for C1 utilization based on formyl-CoA elongation (FORCE) reactions. In an embodiment, the system/method can include acyloin condensations between formyl-CoA and carbonyl-containing molecules. In an embodiment, the system/method can include a reactions catalyzed by the enzyme 2-hydroxyacyl-CoA lyase (HACL).